United Therapeutics Corporation/ US91307C1027 /
| 2024-11-08 10:00:00 PM | Chg. +7.4300 | Volume | Bid12:55:50 AM | Ask12:55:50 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 410.0000USD | +1.85% | 498,743 Turnover: 117.86 mill. |
339.1000Bid Size: 100 | 666.6500Ask Size: 200 | 18.3 bill.USD | - | 19.49 |
Assets
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 489.3000 | 545.7000 | 699.7000 | 738.5000 | 731.6000 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | 2.3000 | 502.7000 | 442.6000 | 767.5000 | 1,149.6000 | ||||||
| Fixed Assets | - | 1,431.5000 | 1,633 | 2,048.9000 | 2,447.8000 | ||||||
| Inventories | 100 | 107.9000 | 101 | 93.4000 | 86.5000 | ||||||
| Accounts Receivable | 214.5000 | 297.1000 | 175.7000 | 151.4000 | 157.4000 | ||||||
| Cash and Cash Equivalents | 1,023 | 705.1000 | 669.2000 | 738.4000 | 738.7000 | ||||||
| Current Assets | 1,424.8000 | 1,447.9000 | 1,768 | 1,864.5000 | 2,167.2000 | ||||||
| Total Assets | 2,325.6000 | 2,879.4000 | 3,401 | 3,913.4000 | 4,615 | ||||||
Liabilities
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | - | - | ||||||
| Long-term debt | - | 250 | 250 | 600 | 800 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 600 | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 474.3000 | 777.6000 | 612.4000 | 1,133 | 1,219.8000 | ||||||
| Share Capital | .7000 | .7000 | .7000 | .7000 | .7000 | ||||||
| Total Equity | 1,851.3000 | 2,101.8000 | 2,788.6000 | 2,780.4000 | 3,395.2000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 2,325.6000 | 2,879.4000 | 3,401 | 3,913.4000 | 4,615 | ||||||
Income Statement
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,598.8000 | 1,725.3000 | 1,627.8000 | 1,448.8000 | 1,483.3000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 1,061.7000 | 814.9000 | 805.4000 | -187.6000 | 593.6000 | ||||||
| Interest Income | -3.9000 | -9 | 14.7000 | 0.0000 | 5.1000 | ||||||
| Income Before Taxes | 1,060.2000 | 769.5000 | 758.9000 | -165 | 638.9000 | ||||||
| Income Taxes | -346.5000 | -351.6000 | -169.7000 | 60.5000 | -124.1000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 713.7000 | 417.9000 | 589.2000 | -104.5000 | 514.8000 | ||||||
Per Share
Cash Flow
| 2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 643.6000 | 474.2000 | 778.4000 | -206.6000 | 755.7000 | ||||||
| Cash Flow from Investing Activities | 48.3000 | -835.6000 | -820.6000 | -335.4000 | -738.5000 | ||||||
| Cash Flow from Financing | -497.7000 | 43.3000 | 6.3000 | 611.2000 | -16.9000 | ||||||
| Decrease / Increase in Cash | 191.2000 | -317.9000 | -35.9000 | 69.2000 | .3000 | ||||||
| Employees | 750 | 800 | 860 | 920 | - | ||||||
